Stockreport

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]

Cullinan Therapeutics, Inc.  (CGEM) 
PDF The company is exploring development of its CD19xCD3 T cell engager CLN-978 in autoimmune disorders Cash and investments of $468.3 million as of December 31, 2023 con [Read more]